Influence of Age and Sex on Serum Copper and Ceruloplasmin Levels

Yunice, Aniece A.; Lindeman, Robert D.; Czerwinski, Anthony W.; Clark, Mervin L.

doi:10.1093/geronj/29.3.277

Cited by 44 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Could the rising ceruloplasmin levels in PD be explained on the basis of normal aging? This is unlikely; in our study; the controls showed no significant correlation with age, in keeping with previous studies of normal subjects that have found either a slight decrease in ceruloplasmin levels with age [19] or no significant difference [20].…”

Section: Discussionsupporting

confidence: 88%

Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease

Bharucha

Vincent³

et al. 2008

J Neurol

View full text Add to dashboard Cite

Ceruloplasmin functions as a ferroxidase in iron metabolism. Parkinson's disease (PD) is characterized by an increase in brain iron. We postulated that lower circulating ceruloplasmin levels in PD would result in rapid brain iron accumulation and an earlier age of onset. Consecutive PD patients were separated into subgroups with younger (< or = 60 years, n = 62) and older ages of onset (> 60, n = 29), and compared to non-PD controls (n = 40). A one-way ANOVA comparing ceruloplasmin levels showed a very robust effect [F(2,128) = 46.4, p < 1e-99]. Post hoc analysis demonstrated that the younger-onset PD subgroup [22.0 mg/dl +/- 6.5 SD] had a lower mean ceruloplasmin level compared to the older-onset PD subgroup [35.7 +/- 10.4] and controls [35.6 +/- 8.4], whose levels did not differ from each other. Ceruloplasmin levels showed robust correlation with age of onset in all 91 PD patients [r = 0.56, r(2) = 0.31, p < 0.0001] but not in the non-PD controls [r = 0.16, r(2) = 0.03, not significant]. Mode of onset and duration of PD showed no relationship to ceruloplasmin. Serum copper and ferritin, available in most patients, did not differ between the PD subgroups. Younger-onset PD patients have significantly lower levels of serum ceruloplasmin compared to those with older-onset PD. Ceruloplasmin may play a role in the etiopathogenesis of younger-onset PD patients and merits further study.

show abstract

Section: Discussionsupporting

confidence: 88%

Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease

Bharucha

Vincent³

et al. 2008

J Neurol

View full text Add to dashboard Cite

show abstract

“…In both normal and DM subjects, no change with aging has been reported by several researchers [19][20][21][22], while a tendency toward increase has also been reported by others [23,24]. Our report demonstrates that serum Cp increases significantly with aging in normal adults but not in DM patients.…”

supporting

confidence: 71%

Increase in Serum Ceruloplasmin with Aging is not Observed in Type 2 Diabetes.

et al. 2000

View full text Add to dashboard Cite

Abstract.Changes of serum ceruloplasmin (Cp) levels have been reported in many conditions including diabetes mellitus (DM), in which the serum Cp levels were increased. In this study, we have examined the influence of aging on serum Cp levels in normal individuals and in individuals with DM. Serum Cp levels were measured in 85 outpatients with type 2 diabetes (type 2 DM group) as well as in 71 healthy individuals (control group). All patients recruited for this study were negative for the glutamic acid decarboxylase (GAD) antibody.The subjects were sub-grouped based on their ages (< 55 and 55 <_ ). The serum Cp levels in the control group increased significantly with aging (r=0.325, p<0.0055), while levels in the type 2 DM group did not (r=0.091, p0.4079).The levels in the type 2 DM group (< 55) were significantly higher than those in the control group (< 55) (p =0.0029), while the Cp levels in the type 2 DM group (55<_) were not different from those in the control group (55<_) (p=0.4187).An age-related increase of serum Cp levels was observed in normal individuals, but this change was not observed in type 2 DM patients since serum Cp levels in type 2 DM patients of all ages were similar to the levels in normal elderly individuals.

show abstract

“…In the whole control material there was significant sex difference with higher S-Zn and lower S-Cu concentrations in the males. This sex difference has been reported by some authors (Lindeman et al, 1971;Hartoma, 1977) but not by others (Halsted and Smith, 1970;Yunice et al, 1974). Lower S-Zn concen- The results are given as the mean ?…”

Section: Discussionsupporting

confidence: 44%

Zinc and Copper Metabolism in Phenytoin Therapy

Palm¹,

Hallmans²

1982

Epilepsia

View full text Add to dashboard Cite

The effect of phenytoin (PHT) on the metabolism of zinc (Zn) and copper (Cu) has been studied during treatment for epilepsy. Eleven previously untreated epileptics were followed from the start of therapy together with 20 patients on long-term therapy. In eight untreated epileptic males low serum concentrations of Zn (S-Zn) were found. At the start of therapy increased S-Zn and S-Cu concentrations were noted. After 1 month of therapy S-Zn was at pretherapy levels but S-Cu was still increased. No changes in the urinary excretion of the metals or in the CSF-Zn concentrations were registered. In the patients on long-term therapy S-Zn was unchanged while S-Cu and S-ceruloplasmin were increased significantly compared with age- and sex-matched controls. It is postulated that the drug may cause a relative zinc deficiency through a chelate binding between Zn and PHT and/or an increased absorption and accumulation of Cu. These effects may be of importance in the development of intoxication symptoms and may also influence the effectiveness of seizure control.

show abstract

Influence of Age and Sex on Serum Copper and Ceruloplasmin Levels

Cited by 44 publications

References 0 publications

Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease

Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson’s disease

Increase in Serum Ceruloplasmin with Aging is not Observed in Type 2 Diabetes.

Zinc and Copper Metabolism in Phenytoin Therapy

Contact Info

Product

Resources

About